0001209191-22-060440.txt : 20221209 0001209191-22-060440.hdr.sgml : 20221209 20221209090153 ACCESSION NUMBER: 0001209191-22-060440 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221207 FILED AS OF DATE: 20221209 DATE AS OF CHANGE: 20221209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Link David Charles CENTRAL INDEX KEY: 0001889464 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39871 FILM NUMBER: 221453749 MAIL ADDRESS: STREET 1: 2100 E 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 BUSINESS PHONE: 605-679-6980 MAIL ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-07 0 0001833214 SAB Biotherapeutics, Inc. SABS 0001889464 Link David Charles 2100 E 54TH STREET NORTH SIOUX FALLS SD 57104 1 0 0 0 Common Stock 2022-12-07 4 A 0 41493 1.205 A 57313 D Warrant (Common Stock) 1.08 2022-12-07 4 A 0 41493 A 2023-06-07 2027-12-07 Common Stock 41493 41493 D On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance. The Reporting Person states that the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities other than those directly owned by the Reporting Person for the purpose of Section 16, or for any other purpose. /s/ David Charles Link 2022-12-09